

# **Pharmacokinetics and Pharmacodynamics of Biotech Drugs**

Principles and Case Studies in Drug Development

*Edited by  
Bernd Meibohm*



WILEY-VCH Verlag GmbH & Co. KGaA



**Pharmacokinetics  
and Pharmacodynamics  
of Biotech Drugs**

*Edited by  
Bernd Meibohm*

## ***Related Titles***

M.S. Chorghade (Ed.)

### **Drug Discovery and Development**

**2 Volumes**

2006. ISBN 0-471-39846-2

J. Knäblein (Ed.)

### **Modern Biopharmaceuticals**

**4 Volumes**

**Design, Development and Optimization**

2005. ISBN 3-527-31184-X

M. Schleef (Ed.)

### **DNA-Pharmaceuticals**

**Formulation and Delivery in Gene Therapy, DNA Vaccination  
and Immunotherapy**

2005. ISBN 3-527-31187-4

O. Kayser, R.H. Müller (Eds.)

### **Pharmaceutical Biotechnology**

**Drug Discovery and Clinical Applications**

2004. ISBN 3-527-30554-8

R.J.Y. Ho, M. Gibaldi

### **Biotechnology and Biopharmaceuticals**

**Transforming Proteins and Genes into Drugs**

2003. ISBN 0-471-20690-3

# **Pharmacokinetics and Pharmacodynamics of Biotech Drugs**

Principles and Case Studies in Drug Development

*Edited by  
Bernd Meibohm*



WILEY-VCH Verlag GmbH & Co. KGaA

#### **The Editor**

##### ***Prof. Dr. Bernd Meibohm***

University of Tennessee  
Health Science Center  
Department of Pharmaceutical Sciences  
College of Pharmacy  
874 Union Ave. Suite 5p  
Memphis, TN 38163  
USA

■ All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

##### **British Library Cataloguing-in-Publication Data:**

A catalogue record for this book is available from the British Library

##### **Bibliographic information published by**

##### **The Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at  
<<http://dnb.ddb.de>>

© 2006 WILEY-VCH Verlag GmbH & Co. KGaA,  
Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Composition** ProSatz Unger, Weinheim

**Printing** Strauss GmbH, Mörlenbach

**Bookbinding** Litges & Dopf Buchbinderei GmbH,  
Heppenheim

Printed in the Federal Republic of Germany

Printed on acid-free paper

**ISBN-13:** 978-3-527-31408-9

**ISBN-10:** 3-527-31408-3

## Foreword

Pharmacokinetics and pharmacodynamics (PK/PD) have become essential disciplines in drug research and development. Rational use of PK/PD allows for better decision making and streamlines dose optimization. In the past, PK/PD concepts have been primarily been applied to the development of small drug molecules. However, in recent years more and more drug candidates come from the field of biotechnology and are larger molecules. *Pharmacokinetics and Pharmacodynamics of Biotech Drugs* gives an excellent overview of the state of the art of applying PK/PD concepts to large molecules.

After a comprehensive introduction, the basic PK/PD properties of peptides, monoclonal antibodies, antisense oligonucleotides and gene delivery vectors are reviewed. In the second part, the book covers a number of challenges and opportunities in this field such as bioanalytical methods, bioequivalence and pulmonary delivery. The text finishes with a detailed presentation of some real-life examples and case studies which should be of particular interest to the reader and integrate many of the concepts presented earlier in the text.

The book was written by a group of international expert scientists in the field. It is well-structured and easy to follow. The book is of great value for everybody working in this area.

*Hartmut Derendorf, Ph.D.*  
Distinguished Professor and Chairman  
Department of Pharmaceutics  
University of Florida





## Preface

In recent years, biotechnologically-derived drugs (biotech drugs) including proteins, peptides, monoclonal antibodies and antibody fragments, as well as antisense oligonucleotides and DNA preparations for gene therapy, have been a major focus of research and development (R&D) efforts in the pharmaceutical industry, and biotech drugs constitute already a sizable fraction of the medications used in clinical practice.

Pharmacokinetic (PK) and pharmacodynamic (PD) concepts impact every stage of the drug development process starting from lead optimization to the design of Phase III pivotal trials. PK and PK/PD evaluations are widely considered cornerstones in the development of new drug products and are usually deeply embedded in the discovery and development plan. The widespread application of PK/PD concepts in all phases of drug development has repeatedly been promoted by industry, academia, and regulatory authorities, most recently through FDA's Critical Path to New Medical Products initiative and the concept of integrated model-based drug development.

An understanding of PK and PD and the related dose-concentration-effect relationship is crucial to any drug – including biotech products – since it lays the foundation for dosing regimen design and rational clinical application. While general PK and PD principles are just as applicable to biotech agents as they are to traditional small molecule drugs, PK and PK/PD analyses of biotech agents frequently pose extra challenges related to factors such as their similarity to endogenous molecules and/or nutrients and their immunogenicity.

This textbook provides a comprehensive overview on the PK and PD of biotech-derived drug products, highlights the specific requirements and challenges related to PK and PK/PD evaluations of these compounds and provides examples of their application in preclinical and clinical drug development. The impetus for this project originated from the notion that at the time of its initiation there was no comprehensive publication on the market that specifically addressed this topic.

Following a short introduction, the book is structured into three sections: The 'Basics' section discusses individually the pharmacokinetics of peptides, monoclonal antibodies, antisense oligonucleotides and gene delivery vectors. The subsequent 'Challenges and Opportunities' section includes more detailed considerations on selected topics, including technical challenges such as bioanalytical

methodologies, noncompartmental data analysis and exposure-response assessments. It furthermore discusses biopharmaceutical challenges as exemplified by the delivery of oligonucleotides and of peptides and proteins to the lung, and provides insights into the opportunities provided by chemical modification of biotech drugs and the regulatory challenges related to follow-on biologics. The third and final section provides examples for the 'Integration of Pharmacokinetic and Pharmacodynamic Concepts into the Biotech Drug Development Plan', including the preclinical and early clinical development of tasidotin, and the clinical development programs for cetuximab and pegfilgrastim.

The book addresses an audience with basic knowledge in clinical pharmacology, PK and PD, and clinical drug development. It is intended as a resource for graduate students, postdocs, and junior scientists, but also for those more experienced pharmaceutical scientists that have no experience in the PK and PD evaluation of biotech drugs and wish to gain knowledge in this area.

I would like to express my gratitude to all contributors of this project for providing their unique array of expertise to this book project which allowed us to compile a wide variety of viewpoints relevant to the PK and PK/PD evaluation of biotech drugs and derived products. In addition, I would like to thank Dr. Romy Kirsten and Dr. Andrea Pillmann at Wiley-VCH for their assistance in producing this book and Ms. Faith Barcroft for her invaluable text editing.

Finally I would like to dedicate this book to my family for their patience, encouragement and support during this project.

Memphis, Summer 2006

*Bernd Meibohm*

## Contents

|                             |     |
|-----------------------------|-----|
| <b>Foreword</b>             | V   |
| <b>Preface</b>              | VII |
| <b>List of Contributors</b> | XIX |

### Part I: Introduction

|          |  |    |
|----------|--|----|
| <b>1</b> | <b>The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs</b> | 3  |
|          | <i>Bernd Meibohm</i>   |    |
| 1.1      | Introduction   | 3  |
| 1.2      | Biotech Drugs and the Pharmaceutical Industry  | 4  |
| 1.3      | Pharmacokinetics and Pharmacodynamics in Drug Development                                    | 6  |
| 1.4      | PK and PK/PD Pitfalls for Biotech Drugs  | 9  |
| 1.5      | Regulatory Guidance  | 10 |
| 1.6      | Future   | 10 |
| 1.7      | References   | 12 |

### Part II: The Basics

|          |  |    |
|----------|--|----|
| <b>2</b> | <b>Pharmacokinetics of Peptides and Proteins</b> | 17 |
|          | <i>Lisa Tang and Bernd Meibohm</i>               |    |
| 2.1      | Introduction                                     | 17 |
| 2.2      | Administration Pathways                          | 18 |
| 2.2.1    | Administration by Injection or Infusion          | 18 |
| 2.2.2    | Inhalational Administration                      | 23 |
| 2.2.3    | Intranasal Administration                        | 24 |
| 2.2.4    | Transdermal Administration                       | 25 |
| 2.2.5    | Peroral Administration                           | 25 |
| 2.3      | Administration Route and Immunogenicity          | 27 |
| 2.4      | Distribution                                     | 28 |

|       |                               |    |
|-------|-------------------------------|----|
| 2.5   | Elimination                   | 29 |
| 2.5.1 | Proteolysis                   | 32 |
| 2.5.2 | Gastrointestinal Elimination  | 32 |
| 2.5.3 | Renal Elimination             | 32 |
| 2.5.4 | Hepatic Elimination           | 34 |
| 2.5.5 | Receptor-Mediated Endocytosis | 35 |
| 2.6   | Interspecies Scaling          | 36 |
| 2.7   | Conclusions                   | 37 |
| 2.8   | References                    | 38 |

### 3 Pharmacokinetics of Monoclonal Antibodies 45

*Katharina Kuester and Charlotte Kloft*

|         |  |    |
|---------|--|----|
| 3.1     | Introduction   | 45 |
| 3.2     | The Human Immune System  | 46 |
| 3.2.1   | The Cellular Immune Response   | 47 |
| 3.2.2   | The Humoral Immune Response  | 47 |
| 3.3     | Physiological Antibodies   | 48 |
| 3.3.1   | Classes of Antibodies  | 48 |
| 3.3.1.1 | Immunoglobulin G   | 48 |
| 3.3.1.2 | Immunoglobulins A, D, M, and E   | 49 |
| 3.3.2   | Chemical Structure of Antibodies   | 50 |
| 3.4     | Therapeutic Antibodies   | 52 |
| 3.4.1   | Therapeutic Polyclonal Antibodies  | 52 |
| 3.4.2   | Therapeutic mAbs   | 53 |
| 3.4.2.1 | Murine mAbs  | 53 |
| 3.4.2.2 | Chimeric mAbs  | 55 |
| 3.4.2.3 | Humanized mAbs   | 55 |
| 3.4.2.4 | Human mAbs   | 55 |
| 3.4.2.5 | Further Species of mAbs  | 56 |
| 3.5     | Effector Functions and Modes of Action of Antibodies                       | 58 |
| 3.5.1   | Biological Effector Functions of mAbs                                      | 58 |
| 3.5.2   | Modes of Action of mAbs  | 59 |
| 3.5.2.1 | Antibody-Dependent Cellular Cytotoxicity (ADCC)                            | 59 |
| 3.5.2.2 | Complement-Dependent Cytotoxicity  | 60 |
| 3.5.2.3 | Blockage of Interaction between (Patho)Physiological Substance and Antigen | 61 |
| 3.5.2.4 | Conjugated Unlabeled mAbs  | 61 |
| 3.5.2.5 | Radioactively Labeled mAbs   | 61 |
| 3.6     | Prerequisites for mAb Therapy  | 62 |
| 3.6.1   | The Patient  | 62 |
| 3.6.2   | The Antibody   | 63 |
| 3.6.3   | The Target Cell  | 63 |
| 3.6.4   | The Antigen  | 63 |
| 3.7     | Issues in the Bioanalysis of Antibodies                                    | 64 |

|          |   |           |
|----------|---|-----------|
| 3.8      | Catabolism of Antibodies  | 65        |
| 3.8.1    | Proteolytic Degradation   | 65        |
| 3.8.2    | Neonatal Fc Receptor (Fc-Rn)  | 65        |
| 3.9      | Pharmacokinetic Characteristics of mAbs                                     | 68        |
| 3.9.1    | Absorption  | 68        |
| 3.9.2    | Distribution  | 71        |
| 3.9.2.1  | Transport   | 71        |
| 3.9.2.2  | Volume of Distribution  | 72        |
| 3.9.2.3  | Types of Binding  | 74        |
| 3.9.3    | Elimination   | 76        |
| 3.9.3.1  | Clearance   | 76        |
| 3.9.3.2  | Proteolysis   | 76        |
| 3.9.3.3  | Binding to Antigen  | 77        |
| 3.9.3.4  | Binding to Anti-Idiotypic Antibodies  | 77        |
| 3.9.3.5  | Drug Interaction Studies  | 78        |
| 3.9.4    | Comparison of Pharmacokinetics of mAbs and Traditional Small-Molecule Drugs | 78        |
| 3.10     | Pharmacokinetic Modeling of mAbs  | 79        |
| 3.10.1   | Noncompartmental Pharmacokinetic Analysis                                   | 79        |
| 3.10.2   | Individual Compartmental Pharmacokinetic Analysis                           | 80        |
| 3.10.3   | Population Pharmacokinetic Analysis   | 81        |
| 3.10.3.1 | Structural Submodel   | 82        |
| 3.10.3.2 | Statistical Submodel  | 85        |
| 3.10.3.3 | Covariate Submodel  | 85        |
| 3.11     | Pharmacodynamics of mAbs  | 86        |
| 3.12     | Conclusions   | 90        |
| 3.13     | References  | 91        |
| <b>4</b> | <b>Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides</b>  | <b>93</b> |
|          | <i>Rosie Z. Yu, Richard S. Geary, and Arthur A. Levin</i>                   |           |
| 4.1      | Introduction  | 93        |
| 4.2      | Pharmacokinetics  | 96        |
| 4.2.1    | Plasma Pharmacokinetics Across Species                                      | 97        |
| 4.2.2    | Tissue Distribution   | 100       |
| 4.2.3    | Metabolism  | 102       |
| 4.2.4    | Elimination and Excretion   | 105       |
| 4.3      | Pharmacodynamics  | 108       |
| 4.3.1    | Pharmacological Endpoint: Reduction of Target mRNA and Protein              | 109       |
| 4.3.2    | Pharmacological Endpoint: Downstream Effects                                | 113       |
| 4.3.3    | Relationship between ASO Pharmacokinetics and Clinical Outcome              | 113       |
| 4.4      | Summary   | 115       |
| 4.5      | References  | 115       |

## 5 Pharmacokinetics of Viral and Non-Viral Gene Delivery Vectors 121

*Martin Meyer, Gururaj Rao, Ke Ren, and Jeffrey Hughes*

- 5.1 General Overview of Gene Therapy 121
- 5.2 Anatomical Considerations 122
- 5.3 Naked DNA 122
- 5.4 Non-Viral Vectors 124
  - 5.4.1 Polymer-Based Vectors 126
    - 5.4.1.1 Introduction 126
    - 5.4.1.2 Influence of Charge and Size 127
    - 5.4.1.3 Biodistribution and Gene Expression 128
  - 5.4.2 Lipid-Based Vectors 131
    - 5.4.2.1 Introduction 131
    - 5.4.2.2 Influence of Physico-Chemical Properties 133
    - 5.4.2.3 Biodistribution and Gene Expression 134
- 5.5 Viral Vectors 136
  - 5.5.1 rAAV: Properties 136
  - 5.5.2 rAAV Serotype and Biodistribution 138
- 5.6 Summary 139
- 5.7 References 139

## Part III: Challenges and Opportunities

## 6 Bioanalytical Methods Used for Pharmacokinetic Evaluations of Biotech Macromolecule Drugs: Issues, Assay Approaches, and Limitations 147

*Jean W. Lee*

- 6.1 Introduction 147
- 6.2 Bioanalytical Methods for Macromolecule Drug Analysis: Common Considerations 148
  - 6.2.1 Sample Integrity and Analyte Stability 148
  - 6.2.2 Surface Adsorption 149
  - 6.2.3 Process of Method Development and Validation of Bioanalytical Methods for Macromolecule Drug Analysis 150
  - 6.2.4 Reference Standards 151
  - 6.2.5 Drug Compounds that Exist Endogenously 152
  - 6.2.6 Validation Samples, Quality Controls, and Assay Range 153
  - 6.2.7 Protein Binding Problems 153
- 6.3 The Bioanalytical Method Workhorses 154
  - 6.3.1 Ligand-Binding Assays: Immunoassays 157
    - 6.3.1.1 Common Method Approach 157
    - 6.3.1.2 Advantages of Immunoassays 158
    - 6.3.1.3 Issues and Limitations of Immunoassays 158
  - 6.3.2 HPLC-ESI-MS/MS Methods 162

|         |  |     |
|---------|--|-----|
| 6.3.2.1 | Common Method Approach   | 162 |
| 6.3.2.2 | Advantages of HPLC-ESI-MS/MS Methods   | 162 |
| 6.3.2.3 | Issues and Limitations of LC-ESI-MS/MS Methods   | 162 |
| 6.4     | Case Studies   | 167 |
| 6.4.1   | Development and Validation of an ELISA Method for an Antibody Drug   | 167 |
| 6.4.2   | Development and Validation of a Sandwich Immunoradiometric Method Using Commercial Kits for a Recombinant Peptide Drug | 169 |
| 6.4.3   | Development and Validation of LC-MS/MS Method for a Peptide Drug   | 171 |
| 6.5     | Future Perspectives: Emerging Quantitative Methods   | 173 |
| 6.5.1   | Sample Clean-Up  | 173 |
| 6.5.2   | Innovations in MS Instruments  | 173 |
| 6.5.3   | Quantification using Signature Hydrolytic Peptides   | 174 |
| 6.5.4   | Advances in Ligand Reagents Design and Production  | 175 |
| 6.6     | Conclusions  | 175 |
| 6.7     | References   | 176 |

## **7 Limitations of Noncompartmental Pharmacokinetic Analysis of Biotech Drugs 181**

*Arthur B. Straughn*

|     |                                       |     |
|-----|---------------------------------------|-----|
| 7.1 | Introduction                          | 181 |
| 7.2 | The Concept of Volume of Distribution | 182 |
| 7.3 | Calculation of $V_{ss}$               | 183 |
| 7.4 | Pitfalls in Calculating $V_{ss}$      | 185 |
| 7.5 | Results and Discussion                | 187 |
| 7.6 | Conclusions                           | 188 |
| 7.7 | References                            | 188 |

## **8 Bioequivalence of Biologics 189**

*Jeffrey S. Barrett*

|       |   |     |
|-------|---|-----|
| 8.1   | Introduction  | 189 |
| 8.2   | Prevailing Opinion: Science, Economics, and Politics    | 191 |
| 8.3   | Biologics: Time Course of Immunogenicity                | 193 |
| 8.4   | Pharmaceutical Equivalence                              | 196 |
| 8.4.1 | How Changes in Quality Might Affect Safety and Efficacy | 197 |
| 8.5   | Bioequivalence: Metrics and Methods for Biologics?      | 198 |
| 8.6   | Case Study: Low-Molecular-Weight Heparins               | 200 |
| 8.7   | Conclusions   | 205 |
| 8.8   | References  | 206 |

|           |  |            |
|-----------|--|------------|
| <b>9</b>  | <b>Biopharmaceutical Challenges: Pulmonary Delivery of Proteins and Peptides</b> | <b>209</b> |
|           | <i>Kun Cheng and Ram I. Mahato</i>   |            |
| 9.1       | Introduction   | 209        |
| 9.2       | Structure and Physiology of the Pulmonary System                                 | 211        |
| 9.2.1     | Airway Epithelium  | 212        |
| 9.2.2     | Alveolar Epithelium  | 214        |
| 9.3       | Barriers to Pulmonary Absorption of Peptides and Proteins                        | 214        |
| 9.4       | Strategies for Pulmonary Delivery  | 215        |
| 9.4.1     | Intratracheal Instillation   | 215        |
| 9.4.2     | Aerosol Inhalation   | 215        |
| 9.4.2.1   | Aerosol Deposition Mechanisms  | 216        |
| 9.4.2.2   | Devices for Pulmonary Drug Delivery  | 216        |
| 9.5       | Experimental Models  | 220        |
| 9.5.1     | Isolated Perfused Lung Model   | 220        |
| 9.5.2     | Cell Culture Models  | 220        |
| 9.6       | Pulmonary Delivery of Peptides and Proteins                                      | 221        |
| 9.6.1     | Mechanisms of Peptide Absorption after Pulmonary Delivery                        | 221        |
| 9.6.2     | Mechanisms of Protein Absorption after Pulmonary Delivery                        | 222        |
| 9.6.3     | Pulmonary Delivery of Peptides and Proteins                                      | 223        |
| 9.6.3.1   | Insulin  | 223        |
| 9.6.3.2   | Salmon Calcitonin  | 227        |
| 9.6.3.3   | Luteinizing Hormone-Releasing Hormone (LHRH) Agonists/<br>Antagonists            | 229        |
| 9.6.3.4   | Vasopressin  | 230        |
| 9.6.3.5   | Granulocyte Colony-Stimulating Factor (G-CSF)                                    | 231        |
| 9.6.3.6   | Interferons  | 232        |
| 9.6.3.7   | TSH, FSH, and HCG  | 233        |
| 9.6.3.8   | Elastase Inhibitors  | 233        |
| 9.7       | Limitations of Aerosol Delivery  | 234        |
| 9.8       | Summary  | 235        |
| 9.9       | References   | 235        |
| <b>10</b> | <b>Biopharmaceutical Challenges: Delivery of Oligonucleotides</b>                | <b>243</b> |
|           | <i>Lloyd G. Tillman and Gregory E. Hardee</i>                                    |            |
| 10.1      | Introduction   | 243        |
| 10.2      | ASOs: The Physico-Chemical Properties  | 244        |
| 10.3      | Local Administration   | 246        |
| 10.3.1    | Ocular Delivery  | 246        |
| 10.3.2    | Local Gastrointestinal Delivery  | 247        |
| 10.3.2.1  | Rectal Dosing  | 247        |
| 10.3.2.2  | Oral Dosing  | 248        |
| 10.3.3    | Pulmonary Delivery   | 249        |
| 10.3.3.1  | Formulation Considerations   | 251        |



|          |   |     |
|----------|---|-----|
| 10.3.3.2 | Deposition and Uptake                       | 251 |
| 10.3.4   | Delivery to the Brain                       | 253 |
| 10.3.5   | Topical Delivery                            | 253 |
| 10.3.6   | Other Local Delivery Approaches             | 254 |
| 10.4     | Systemic Delivery                           | 255 |
| 10.4.1   | Parenteral Routes                           | 255 |
| 10.4.1.1 | Sustained-Release Subcutaneous Formulations | 256 |
| 10.4.2   | Oral Delivery                               | 257 |
| 10.4.2.1 | Permeability                                | 258 |
| 10.4.2.2 | Systemic Bioavailability                    | 260 |
| 10.5     | Conclusions                                 | 265 |
| 10.6     | References                                  | 266 |

## **11 Custom-Tailored Pharmacokinetics and Pharmacodynamics via Chemical Modifications of Biotech Drugs 271**

*Francesco M. Veronese and Paolo Caliceti*

|        |   |     |
|--------|---|-----|
| 11.1   | Introduction  | 271 |
| 11.2   | Polymers Used in Biotechnological Drug PEGylation                     | 272 |
| 11.3   | Advantages of PEG as Drug Carrier                                     | 273 |
| 11.4   | Chemical Aspects Critical for the Pharmacokinetics of Drug Conjugates | 274 |
| 11.5   | Insulin   | 279 |
| 11.6   | Interferons   | 282 |
| 11.7   | Avidin  | 285 |
| 11.8   | Non-Peptide Drug Conjugation  | 288 |
| 11.8.1 | Amphotericin B  | 289 |
| 11.8.2 | Camptothecins   | 290 |
| 11.8.3 | Cytosine Arabinoside (Ara-C)  | 291 |
| 11.9   | Concluding Remarks  | 292 |
| 11.10  | References  | 292 |

## **12 Exposure–Response Relationships for Therapeutic Biologic Products 295**

*Mohammad Tabrizi and Lorin K. Roskos*

|          |   |     |
|----------|---|-----|
| 12.1     | Introduction                                      | 295 |
| 12.2     | Overview of Pharmacokinetics and Pharmacodynamics | 295 |
| 12.2.1   | Pharmacokinetics                                  | 295 |
| 12.2.1.1 | Absorption  | 296 |
| 12.2.1.2 | Distribution                                      | 296 |
| 12.2.1.3 | Elimination                                       | 296 |
| 12.2.1.4 | Immunogenicity                                    | 298 |
| 12.2.2   | Pharmacodynamics                                  | 298 |
| 12.3     | Hormones  | 300 |
| 12.3.1   | Insulin   | 301 |

|          |   |     |
|----------|---|-----|
| 12.3.2   | Parathyroid Hormone                             | 302 |
| 12.4     | Cytokines                                       | 303 |
| 12.4.1   | Interleukin-2                                   | 305 |
| 12.5     | Growth Factors                                  | 306 |
| 12.5.1   | Epoetin- $\alpha$                               | 307 |
| 12.6     | Soluble Receptors                               | 308 |
| 12.6.1   | Etanercept                                      | 308 |
| 12.7     | Monoclonal Antibodies (mAbs)                    | 310 |
| 12.7.1   | Therapeutic Antibodies in Inflammatory Diseases | 311 |
| 12.7.1.1 | Anti-TNF- $\alpha$ Antibodies                   | 314 |
| 12.7.1.2 | Efalizumab                                      | 316 |
| 12.7.1.3 | Omalizumab                                      | 317 |
| 12.7.2   | Therapeutic Antibodies in Oncology              | 317 |
| 12.7.2.1 | Rituximab                                       | 318 |
| 12.7.2.2 | Bevacizumab                                     | 319 |
| 12.7.2.3 | Trastuzumab                                     | 320 |
| 12.8     | Conclusions                                     | 321 |
| 12.9     | References                                      | 321 |

#### **Part IV: Examples for the Integration of Pharmacokinetic and Pharmacodynamic Concepts Into the Biotech Drug Development Plan**

|           |   |            |
|-----------|---|------------|
| <b>13</b> | <b>Preclinical and Clinical Drug Development of Tasidotin, a Depsi-Pentapeptide Oncolytic Agent</b> | <b>331</b> |
|           | <i>Peter L. Bonate, Larry Arthaud, and Katherine Stephenson</i>                                     |            |
| 13.1      | Introduction  | 331        |
| 13.2      | The Dolastatins   | 331        |
| 13.3      | Discovery and Preclinical Pharmacokinetics of Tasidotin   | 333        |
| 13.4      | Preclinical Pharmacology of Tasidotin and ILX651-C-Carboxylate                                      | 334        |
| 13.5      | Toxicology of Tasidotin   | 334        |
| 13.6      | Clinical Pharmacology and Studies of Tasidotin in Patients with Solid Tumors                        | 335        |
| 13.7      | Clinical Pharmacology of ILX651-C-Carboxylate   | 341        |
| 13.8      | Exposure–Response Relationships   | 342        |
| 13.9      | Discussion  | 343        |
| 13.10     | Summary   | 349        |
| 13.11     | References  | 349        |

|           |   |            |
|-----------|---|------------|
| <b>14</b> | <b>Clinical Drug Development of Cetuximab, a Monoclonal Antibody</b>  | <b>353</b> |
|           | <i>Arno Nolting, Floyd E. Fox, and Andreas Kovar</i>  |            |
| 14.1      | Introduction  | 353        |
| 14.2      | Specific Considerations in Oncologic Drug Development   | 354        |
| 14.3      | Introduction to the Clinical Pharmacokinetics of Cetuximab  | 356        |
| 14.4      | Early Attempts to Characterize the PK of Cetuximab  | 356        |
| 14.5      | PK of Cetuximab Following Pooling of Data Across All Studies  | 357        |
| 14.5.1    | Comparison of Single-Dose PK Parameters at Various Dose Levels  | 357        |
| 14.5.1.1  | Maximum Serum Concentration   | 357        |
| 14.5.1.2  | Area Under the Concentration-Time Curve   | 359        |
| 14.5.1.3  | Clearance   | 360        |
| 14.5.1.4  | Elimination Half-Life   | 361        |
| 14.5.1.5  | Volume of Distribution  | 361        |
| 14.5.2    | Drug Metabolism and <i>in-vitro</i> Drug-Drug Interaction Studies   | 362        |
| 14.5.3    | Comparison of Single- and Multiple-Dose PK at the Approved Dosing Regimen   | 362        |
| 14.6      | Characterization of Cetuximab PK by a Population PK Approach  | 364        |
| 14.7      | Drug-Drug Interaction Studies   | 366        |
| 14.8      | Conclusions   | 369        |
| 14.9      | References  | 370        |
| <b>15</b> | <b>Integration of Pharmacokinetics and Pharmacodynamics Into the Drug Development of Pegfilgrastim, a Pegylated Protein</b> | <b>373</b> |
|           | <i>Bing-Bing Yang</i>   |            |
| 15.1      | Introduction  | 373        |
| 15.2      | Overview of Filgrastim Pharmacokinetics   | 374        |
| 15.3      | The Making of Pegfilgrastim   | 375        |
| 15.4      | Preclinical Pharmacokinetics and Pharmacodynamics of Pegfilgrastim  | 376        |
| 15.5      | Pharmacokinetic and Pharmacodynamic Modeling  | 379        |
| 15.6      | Clinical Pharmacokinetics and Pharmacodynamics of Pegfilgrastim   | 381        |
| 15.7      | Basis for the Fixed-Dose Rationale  | 385        |
| 15.8      | Clinical Evaluation of the Fixed Dose   | 389        |
| 15.9      | Summary   | 391        |
| 15.10     | References  | 391        |
|           | <b>Subject Index</b>  | <b>395</b> |



## List of Contributors

### **Larry Arthaud**

Department of Pharmacokinetics  
Genzyme Corporation  
4545 Horizon Hill Blvd.  
San Antonio, TX 78229  
USA

### **Jeffrey S. Barrett**

Laboratory for Applied PK/PD  
The Children's Hospital of  
Philadelphia  
Abramson Research Center,  
Room 916 H  
34th Street and Civic Center Blvd.  
Philadelphia, PA 19104  
USA

### **Peter L. Bonate**

Department of Pharmacokinetics  
Genzyme Corporation  
4545 Horizon Hill Blvd.  
San Antonio, TX 78229  
USA

### **Paolo Caliceti**

Department of Pharmaceutical  
Sciences  
School of Pharmacy  
University of Padua  
Via Francesco Marzolo, 5  
35131 Padua  
Italy

### **Kun Cheng**

Department of Pharmaceutical  
Sciences  
University of Tennessee Health  
Science Center  
26 S. Dunlap Street  
Memphis, TN 38163  
USA

### **Floyd E. Fox**

Clinical Pharmacology  
ImClone Systems Inc.  
59 ImClone Drive  
Somerville, NJ 08876  
USA

### **Richard S. Geary**

Pharmacokinetics and Drug  
Metabolism  
Isis Pharmaceuticals  
1896 Rutherford Road  
Carlsbad, CA 92008  
USA

### **Gregory E. Hardee**

Quality Assurance  
Isis Pharmaceuticals  
1896 Rutherford Road  
Carlsbad, CA 92008  
USA

**Jeffrey R. Hughes**

Pharmaceutical Sciences  
College of Pharmacy  
University of Florida  
Box 100494, JHMH  
Gainesville, FL 32610  
USA

**Charlotte Kloft**

Department of Clinical Pharmacy  
Faculty of Pharmacy  
Martin-Luther-Universität  
Halle-Wittenberg  
Wolfgang-Langenbeck-Strasse 4  
06120 Halle  
Germany

**Katharina Kuester**

Department of Clinical Pharmacy  
Institute of Pharmacy  
Freie Universität Berlin  
Kelchstrasse 31  
12169 Berlin  
Germany

**Andreas Kovar**

Clinical Pharmacology  
and Pharmacokinetics  
Merck KGaA  
Frankfurter Strasse 250  
64293 Darmstadt  
Germany

**Jean W. Lee**

Pharmacokinetics and Drug  
Metabolism  
Protein Labs  
Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, CA 91320  
USA

**Arthur A. Levin**

Isis Pharmaceuticals  
1896 Rutherford Road  
Carlsbad, CA 92008  
USA

**Ram I. Mahato**

Department of Pharmaceutical  
Sciences  
College of Pharmacy  
University of Tennessee Health  
Science Center  
26 S. Dunlap Street  
Memphis, TN 38163  
USA

**Bernd Meibohm**

Department of Pharmaceutical  
Sciences  
College of Pharmacy  
University of Tennessee Health  
Science Center  
874 Union Avenue, Suite 5p  
Memphis, TN 38163  
USA

**Martin Meyer**

Department of Pharmaceutics  
College of Pharmacy  
Box 100494, JHMH  
University of Florida  
Gainesville, FL 32610  
USA

**Arno Nolting**

Clinical Pharmacology and  
Pharmacokinetics  
Merck KGaA  
Frankfurter Strasse 250  
64293 Darmstadt  
Germany

**Gururaj Rao**

Department of Pharmaceutics  
College of Pharmacy  
Box 100494, JHMH  
University of Florida  
Gainesville, FL 32610  
USA

**Ke Ren**

Department of Pharmaceutics  
College of Pharmacy  
Box 100494, JHMH  
University of Florida  
Gainesville, FL 32610  
USA

**Lorin K. Roskos**

Pharmacokinetics and Toxicology  
Amgen Inc.  
6701 Kaiser Drive  
Fremont, CA 94555  
USA

**Katherine Stephenson**

Department of Pharmacokinetics  
Genzyme Corporation  
4545 Horizon Hill Blvd.  
San Antonio, TX 78229  
USA

**Arthur B. Straughn**

Department of Pharmaceutical  
Sciences  
College of Pharmacy  
University of Tennessee Health  
Science Center  
874 Union Avenue, Suite 5p  
Memphis, TN 38163  
USA

**Mohammad Tabrizi**

Pharmacokinetics and Toxicology  
Amgen Inc.  
6701 Kaiser Drive  
Fremont, CA 94555  
USA

**Lisa Tang**

Department of Pharmaceutical  
Sciences  
College of Pharmacy  
University of Tennessee Health  
Science Center  
874 Union Avenue, Room 105p  
Memphis, TN 38163  
USA

**Lloyd G. Tillman**

Pharmaceutical Development  
Isis Pharmaceuticals  
1896 Rutherford Road  
Carlsbad, CA 92008  
USA

**Francesco M. Veronese**

Department of Pharmaceutical  
Sciences  
School of Pharmacy  
University of Padua  
Via Francesco Marzolo, 5  
35131 Padua  
Italy

**Bing-Bing Yang**

Pharmacokinetics and Drug  
Metabolism  
Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, CA 91320  
USA

**Rosie Z. Yu**

Department of Pharmacokinetics  
Isis Pharmaceuticals  
1896 Rutherford Road  
Carlsbad, CA 92008  
USA





**Part I**  
**Introduction**



# 1

## The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs

*Bernd Meibohm*

### 1.1

#### Introduction

During the past two decades, advances in biotechnology have triggered the development of numerous new drug products. This group of so-called biotech drugs is a subset of the therapeutic group of biologics. Therapeutic biologic products, or biologics, are defined by the U.S. Food and Drug Administration (FDA) as any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment or cure of diseases or injuries of man. Biologics are a subset of drug products distinguished by their manufacturing process. While classical drugs are synthesized via a chemical process, biologics are manufactured utilizing biological processes and are typically derived from living material – human, plant, animal, or microorganism. Biotech drugs can be considered as those biologics that are manufactured using biotechnology-based production processes.

The similarity in the drug development and evaluation process for biotech drugs and conventional, chemically synthesized drugs has recently been acknowledged in the FDA's 2003 decision to transfer certain product oversight responsibilities from the Center for Biologics Evaluation and Research (CBER) to the Center for Drug Evaluation and Research (CDER). The biologics for which oversight was transferred include monoclonal antibodies for *in vivo* use, proteins intended for therapeutic use, including cytokines (e.g., interferons), enzymes (e.g., thrombolytics), growth factors, and other novel proteins that are derived from plants, animals, or microorganisms, including recombinant versions of these products, and other non-vaccine and non-allergenic therapeutic immunotherapies. Classical biologics such as blood, blood components and vaccines remain under the regulatory authority of the CBER. Even under this new structure, however, the biologic products transferred to the CDER will continue to be regulated as licensed biologics – that is, a Biologic License Application (BLA) must be submitted to obtain marketing authorization as compared to a New Drug Application (NDA) which is used for traditional, chemically manufactured drug products.

For the purpose of this book, biotech drugs include not only therapeutically used peptides and proteins, including monoclonal antibodies, but also oligonucleotides and DNA preparations for gene therapy. Although oligonucleotides are, due to their chemically defined production process, classified by the FDA as classical drugs requiring an NDA prior to marketing authorization, and DNA preparations for gene therapy are regulated by the CBER, they are both included in the class of biotech drugs as their therapeutic application relies heavily on the principles of molecular biology and they are considered by analysts as biotech compounds.


## 1.2

### **Biotech Drugs and the Pharmaceutical Industry**


In parallel with the development of the discipline of biotechnology during the past two decades, an increasing fraction of pharmaceutical R&D has been devoted to biotechnology-derived drug products. It has been estimated that more than 250 million patients have benefited from already approved biotechnology medicines to treat or prevent heart attacks, stroke, multiple sclerosis, leukemia, hepatitis, rheumatoid arthritis, breast cancer, diabetes, congestive heart failure, kidney cancer, cystic fibrosis and other diseases [1]. This number is expected to increase significantly with the introduction of new biotech drugs into the marketplace. According to a survey by the Pharmaceutical Research and Manufacturers of America (PhRMA) in 2004, 324 biotechnology medicines were in development for almost 150 diseases. These include 154 medicines for cancer, 43 for infectious diseases, 26 for autoimmune diseases, and 17 for AIDS/HIV and related conditions. These potential medicines – all of which were at the time of the survey either in human clinical trials or under review by the FDA – will enlarge the list of 108 biotechnology medicines already approved and available to patients (Fig. 1.1) [1].

Biotech and genomic companies currently perform almost one-fifth of all pharmaceutical R&D, and this figure is set to double during the next 10 years [2]. It has been suggested that over half of all the New Active Substances developed during the next 10–15 years will result from research into antibodies alone. Biotechnology products accounted for more than 35% of the 37 New Active Substances that were launched in 2001 [2]. This success in drug development is underlined by the fact that several biotech drugs have achieved blockbuster status, earning more than US\$ 1 billion in annual sales, including Epoetin- $\alpha$  (Epogen/Procrit/Epex), interferon- $\alpha$ 2b (IntronA, PEG-Intron/Rebetron combination therapy), and filgrastim (Neupogen) [3].

Since the development of biotech drugs generally rests on a fundamental understanding of the related disease, their clinical development has also proven to be more successful than for conventional, chemically derived small-molecule drugs. Only 8% of the new chemical entities that entered the clinical phases of drug development between 1996 and 1998 reached the market, compared to 34% of biotech drugs (Fig. 1.2). This means that biologics have, at the time of their first-in-



**Fig. 1.1** Advances in biotech drug development (beyond 2003 projected; with permission from Macmillan Publishers Ltd. [19]).



**Fig. 1.2** Success rates for clinical drug development are much higher for biologics than for traditional, chemically defined drug compounds. NCE: New chemical entity (modified from [2]).

man studies, a fourfold greater chance than traditional, chemically defined drugs of making it into the marketplace. Thus, greater use of biologics will likely reduce the attrition rate at every stage of the clinical drug development process [2]. Based on these facts, it can be predicted that biotech drugs will play a major – if not dominant – role in the drug development arena of the next decades.

### 1.3

#### Pharmacokinetics and Pharmacodynamics in Drug Development

The general paradigm of clinical pharmacology is that administration of a dose or the dosing regimen of a drug results in defined drug concentrations in various body compartments and fluids. These are, in turn, the driving force for the drug's desired and undesired effects on the human body that collectively constitute the drug's efficacy and safety profile. Based on this paradigm, the basis for the pharmacotherapeutic use of biotech drugs is similar to that of small molecules – a defined relationship between the intensity of the therapeutic effect and the amount of drug in the body or, more specifically, the drug concentration at its site of action (i. e., an exposure–response relationship). The relationship between the administered dose of a drug, the resulting concentrations in body fluids and the intensity of produced outcome may be either simple or complex, and thus obvious or hidden. However, if no simple relationship is obvious, it would be misleading to conclude *a priori* that no relationship exists at all rather than that it is not readily apparent [4, 5].

The dose–concentration–effect relationship is defined by the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of a drug. Pharmacokinetics comprises all processes that contribute to the time course of drug concentrations